A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure
The purpose of this study is to compare the effects on heart rate and ventricular arrhythmias (irregular heart beats) of two doses of NatrecorÂ® (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure) versus dobutamine, during the first 24 hours of treatment of decompensated congestive heart failure (CHF).
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Natrecor (Nesiritide) Versus Dobutamine Therapy for Symptomatic, Decompensated CHF: A Safety Study Using 24-Hour Holter Monitoring - The PRECEDENT Trial: Prospective, Randomized Evaluation of Cardiac Ectopy With Dobutamine or Natrecor Therapy|
- Average heart rate; average hourly premature ventricular beats; average hourly repetitive beats, all expressed as a change from baseline
- Incidence of tachycardia through 24 hours; Incidence of tachycardia, pain, and injection site reaction through 14 days .
|Study Start Date:||August 1998|
|Study Completion Date:||February 1999|
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00270400
|Study Director:||Scios, Inc. Clinical Trial||Scios, Inc.|